Core Contraceptive Efficacy

The primary therapeutic use of this medication is as a continuous form of oral contraception, and it is used for managing pregnancy prevention for women of reproductive age. This use is relevant for patients seeking long-term family planning.

Relief of Painful and Heavy Menstrual Symptoms

This medication offers supportive therapeutic benefit in managing distressing symptoms related to physical discomfort during the menstrual cycle. It is used for addressing the burden of severe monthly pain (dysmenorrhea) and is used for managing excessively heavy or prolonged bleeding (menorrhagia), which are conditions characterized by periods of heightened symptoms. This contributes to easing the overall symptom load and provides support during the menstrual cycle.

Management of Moderate Acne and Gynaecological Support

This medication is applied across domains where additional symptomatic support is needed alongside contraception. It is used for managing symptom clusters that may become intense or disruptive, such as the manifestations of moderate acne vulgaris, including pustules, papules, and excessive skin greasiness. It is also relevant for managing symptoms related to physical discomfort, such as chronic pelvic pain and associated manifestations, in conditions like endometriosis. This offers symptomatic relief for patients experiencing difficult or recurrent episodes of gynaecological discomfort.

Who Can and Cannot Use Диециклен?

The eligibility criteria for Диециклен (Dienogest/Ethinylestradiol) are based strictly on regulatory classification, focusing on established high-risk conditions, primarily related to vascular and hormonal status.

Contraindications (Must Not Use)

The medicine is absolutely contraindicated in women with a history of or genetic predisposition to Venous or Arterial Thromboembolism (VTE/ATE), including stroke, myocardial infarction, deep vein thrombosis, or pulmonary embolism. Use is prohibited for smokers over age 35 and those with uncontrolled hypertension or vascular-complicated diabetes. Known or suspected sex-steroid influenced malignancies, such as breast cancer, also constitute an absolute contraindication. The medicine must not be used during pregnancy or in cases of severe hepatic disease until liver function values have normalized.

Conditional and Age Restrictions

Use is only indicated after menarche (onset of menstruation) and is not indicated after menopause. The medicine is not generally recommended for women who are breastfeeding. Specific conditions require careful medical evaluation: for instance, obesity (BMI > 30 kg/m²) and a history of migraine with aura necessitate a formal risk assessment due to increased vascular risk factors.

Interactions with other medicines and products

The hormonal components of this medication can be affected by other products, potentially leading to a loss of effectiveness or an increased risk of adverse reactions. The primary documented interactions fall into two categories: enzyme-inducing agents and specific antiviral combinations.

Pharmacokinetic Interactions (Enzyme Induction)

• CYP3A Enzyme Inducers: Medicines or herbal products that induce (increase the activity of) the cytochrome P450 3A (CYP3A) enzyme pathway may substantially decrease the blood levels of the dienogest and estradiol components. This mechanism can lead to a reduction in therapeutic effect, resulting in contraceptive failure and/or irregular bleeding. Examples of documented enzyme inducers include certain anticonvulsants (e.g., phenytoin, carbamazepine), some antiretroviral drugs, and the herbal supplement St. John's wort.
• Timing Requirement: If co-administration with a strong CYP3A inducer is unavoidable, the labeling mandates the use of an alternative, non-hormonal method of contraception during co-administration and for up to 28 days following the discontinuation of the inducing agent.

High-Risk Combinations

• Hepatitis C Drug Combinations: Concomitant use with specific combination regimens for Hepatitis C virus (HCV) is contraindicated. These regimens, containing active ingredients such as ombitasvir, paritaprevir, ritonavir, and/or dasabuvir, have been associated with a specific risk of clinically significant elevations in liver enzymes (ALT) when used with estradiol-containing products. Non-hormonal contraception should be used before and during treatment with these HCV regimens.

Диециклен (Dicyclomine) functions as an antimuscarinic agent and a direct smooth muscle relaxant. Its primary biological targets are the muscarinic acetylcholine receptors, specifically subtypes M1, M2, and M3. The molecule acts as a non-selective competitive antagonist at these receptors, preventing the binding of the endogenous neurotransmitter acetylcholine.

The inhibition of acetylcholine binding at M3 receptors, which are coupled to the Gq protein, blocks the resulting intracellular signaling cascade. This blockade prevents the activation of phospholipase C and the subsequent increase in intracellular calcium concentration. Since calcium is essential for the actin-myosin cross-bridging cycle, its restricted availability leads to a reduced contractile state in the smooth muscle cells of the gastrointestinal tract.

Independently, Диециклен also exerts a musculotropic effect via a direct, non-competitive inhibition of smooth muscle contraction. This dual interaction culminates in system-level physiological modulation characterized by reduced gastrointestinal motility and diminished basal muscle tone.

The administration of Диециклен (Dienogest/Ethinylestradiol) follows a precise, continuous cyclic protocol.

Administration Scope

Instruction Classifications (High-Level)

Resulting Procedural Structure

General Procedural Sequence:

• Start the regimen on the first day of the menstrual cycle or when switching from a different method.
• Take one tablet daily, ensuring the intake is at the same time each day.
• Follow the tablet order precisely throughout the 28-day cycle (active ightarrow placebo/hormone-free).

The instructions define a standardized, continuous cyclic protocol where consistent adherence to the fixed daily dose and the sequential order of tablets are key requirements. This structure describes how the active and inactive components are administered in a precise, non-interruptible pattern.

Evidence for Use in Preventing Pregnancy

The medication was evaluated as an oral contraceptive in large-scale Phase III clinical trials involving women of reproductive age. Research systematically monitored the pregnancy rate, tracked using the Pearl Index, and examined characteristics related to menstrual cycle predictability and consistent influence on ovulation. Findings describe patterns observed in the studies that were consistent with the combination acting to influence the reproductive processes that research examined. This evidence contributes to understanding symptom patterns for women relying on hormonal contraception for long-term family planning.

Evidence for Dermatological and Androgen-Related Symptoms

The research base for the medication's use in conditions like moderate acne was studied in Randomized Controlled Trials (RCTs). These studies examined outcomes linked to inflammatory states, measuring changes in acne lesion counts and standardized severity scores. Findings describe patterns observed in the studies that included measurements of change in skin-related metrics compared to baseline measurements. Comparative evidence against the full range of non-hormonal dermatological treatments is often lacking.

Evidence for Managing Painful and Heavy Menstrual Symptoms

Studies explored the medication’s use in managing symptoms related to heavy bleeding (menorrhagia) and pain (dysmenorrhea) using RCTs. Research examined objective measures such as the alkaline hematin method for quantifying menstrual blood loss (MBL) volume and standardized pain scales. Evidence describing MBL patterns may be insufficient when comparing consistency across all related Dienogest-containing hormonal formulations.

Evidence for Use in Endometriosis-Associated Pain

This drug combination was evaluated in comparative and controlled studies to understand its role in women with surgically confirmed endometriosis, a condition marked by chronic pelvic pain. Research examined outcomes related to physical discomfort, including the intensity of chronic pelvic pain, and general Quality of Life (QoL) scores. Follow-up durations were limited in many controlled trials assessing the duration of pain patterns.

Uncertainty and Study Gaps

The overall research landscape contains evidence for its main uses but features several areas where data are still emerging. The evidence is limited regarding detailed comparison of rare outcomes when contrasted with every other specific type of combined hormonal contraceptive currently available. Long-term effects are not fully established beyond intermediate follow-up periods, and research does not determine whether an individual will respond similarly to the group averages described in the published studies.

Key Studies & References Focus on Ethinylestradiol/Dienogest (EE/DNG) Contraceptive Efficacy and Antiandrogenic Properties

Common questions about Диециклен (FAQ)

Q: Is it safe to take this drug if I am pregnant?

A: Official regulatory documents provide a detailed Risk Summary and specific Clinical Considerations regarding the use of this medication during pregnancy. This information is primarily intended for healthcare providers to assess potential risks and benefits. Patients should discuss this information with their healthcare provider to review the data and determine the appropriate course of action based on their individual circumstances.

Q: Does it make you sleepy?

A: According to the official product information, potential side effects of this drug may include effects on the central nervous system (CNS). These effects are sometimes reported as drowsiness, somnolence (sleepiness), or fatigue. Due to the potential for these effects, patients are generally advised to use caution when engaging in activities that require full mental alertness.

Q: Can children 2 years old use it?

A: The official labeling provides specific information regarding the use of this drug in children. Regulatory documents address the safety and effectiveness in pediatric patients, including the age groups for which its use is approved or for which its safety has not been established. Healthcare providers should be consulted to confirm whether the medication is appropriate for use in specific age groups, based on the approved product information.

How to Store and Dispose of Dienogest/Ethinylestradiol (Диециклен)

Official regulatory documents define strict requirements for storing and discarding this combined hormonal contraceptive to maintain product integrity and safety.

Storage outside of the prescribed temperature range can compromise the product's stability and shelf-life. Disposal of expired or unused medicine must follow official pharmaceutical waste procedures. Patients are instructed to consult a pharmacist for guidance on proper disposal, ensuring the product is not discarded via wastewater or general household trash.